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Abstract 
I will offer a conceptual analysis of different notions of structure and function of viral immunogens and 
of different structure-function relationships. My focus will then be on the mechanisms by which the 
desired immune response is induced and why strategies based on three-dimensional molecular antigen 
structures and their rational design are limited in their ability to induce the desired immunogenicity. I 
will look at the mechanisms of action of adjuvants (thus the wordplay with Janeway’s “immunologist’s 
dirty little secret”). Strategies involving adjuvants and other (more successful) vaccination strategies 
rely on taking into account activities and functions (“what is going on”), and not just the structures 
involved (“who is there”), in binding in a “lock and key” fashion. Functional patterns as well as other 
organizational and temporal patterns, I will argue, are crucial for inducing the desired immune response 
and immunogenicity. The 3D structural approach by itself has its benefits – and its limits, which I want 
to highlight by this philosophical analysis, pointing out the importance of structure-function 
relationships. Different functional aspects such as antigenicity, immunogenicity, and immunity need to 
be kept separate and cannot be reduced to three-dimensional structures of vaccines. Taking into account 
different notions of structure and function and their relationships might thus advance our understanding 
of the immune system and rational HIV vaccine design, to which end philosophy can provide useful 
tools. 
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Introduction 
In his seminal 1989 paper, Charles A. Janeway Jr., a key figure in immunology, coined the phrase “the 
immunologist’s dirty little secret” [1], together with what he called the “Landsteinerian fallacy”, 
referring to the fact that the mere presence of a foreign antigen was not equally able and sufficient to 
trigger an adaptive immune response. He was convinced that, for immunogenicity, signals from host 
cells are required in addition to the presence of an antigen. One way in which these additional signals 
could be provided in a setting that did not involve the presence or activity of pathogens was by adding 
so-called “adjuvants”. It became common practice to add aluminum salts or other components as 
adjuvants, without always knowing their exact mechanism of action. Although many details have 
become much better understood in immunology in the decades since then [2], especially since the 
discovery of Toll-like receptors [3] and other pattern recognition receptors, we are still far from 
“approaching the asymptote” [1] in our understanding of the immune system, and many open questions 
remain. 
In this paper, I want to look at how a better understanding of structure-function relationships can clarify 
some conceptual issues underlying the difficulties with developing an HIV-1 vaccine by rational design. 
One underlying mindset responsible for a limited perspective, according to my argument, is the neglect 
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of some issues addressed in the previous introductory paragraph – which I will refer to as the 
“vaccinologist’s dirty little secret”. I will argue that the almost exclusive focus of rational vaccination 
design on three-dimensional molecular shapes of antigens has made it prone to difficulties similar to the 
ones expressed earlier by Janeway. I will then suggest a framework of structure-function relationships 
for understanding the scope and limits of each of the notions of structure and function as immunological 
targets for vaccine development and therapies of HIV/AIDS. 
Vaccinations are often huge success stories, like in the case of smallpox. Other vaccination efforts 
against, for example, the common cold or seasonal influenza are a constant struggle and race against 
time. During the ongoing COVID-19 crisis, massive vaccination efforts have yielded promising results 
in a short time. While, at the time of writing, the widespread use of a vaccine is still at least several 
months away, the speed at which progress has been made in vaccine development has been impressive. 
On other fronts, however, vaccination attempts have been unsuccessful despite massive efforts for 
several decades. HIV-1 is the prime example of a virus – and its accompanying disease – for which it 
has not yet been possible to develop a vaccine. There are a number of reasons, which will be addressed 
throughout this special issue (see also references [4, 5]). In my paper, I want to focus on one particular 
aspect that constitutes a central puzzle for (much of) biology in general and poses a major challenge to 
so-called “rational vaccination design” against HIV-1 in particular: structure-function relationships. 
Both terms – ‘structure’ and ‘function’ – have multiple meanings we need to distinguish first before we 
can draw meaningful relationships between these notions. After offering a conceptual analysis of the 
terms and their respective meanings, we will address the kinds of relationships that can – and cannot – 
be claimed to exist between them. There are a number of general conceptual and theoretical 
ramifications beyond rational vaccination design, but this is a field in which misunderstandings about 
structure-function relationships might have been underlying some major obstacles in attempting to 
design a vaccine rationally. These reasons will be the main focus of the paper. 
‘Structure’ and ‘function’ are polysemic terms 
Most biology textbooks feature the slogan “structure determines function”. Its exact meaning and scope, 
however, are less than clear. Before addressing the relationships between structure and function, let’s 
take a closer look at the terms themselves. Most prominently, when thinking about proteins and other 
molecules, and especially when it comes to components of the immune system, ‘structure’ usually refers 
to the three-dimensional shape of molecules (str3D). This str3D, in turn, is said to be determined by its 
amino acid sequence – another kind of structure (strseq). The sequence of amino acids, again, depends 
on the corresponding strseq of nucleotides; first DNA, which is then transcribed into RNA and 
consequently translated into protein. From a simple reductionist view, but originally phrased in terms of 
“information”, this belongs to the so-called “central dogma of molecular biology” [6]. 
DNA → RNA → protein 
In a next step, we have the widespread belief that a protein’s structure will determine its function. Thus, 
according to the reductionist ideal, knowing the genetic code would allow us to predict all of the protein 
structures and functions encoded in a genome. Unfortunately, this linear chain of determination 
relations, strseq→ str3D→ function, does not hold. Besides the intricacies of how nucleotides get 
translated and transcribed into protein, the protein folding problem still poses a major challenge, and 
intrinsically unstructured proteins [7] and multifunctional “moonlighting” proteins [8] further defy this 
linear chain of determination. 
While these high expectations have been disappointed for many reasons, one fundamental issue 
remaining is the actual meaning of the word ‘function’ and how much of a genome should be considered 
to be functional or “junk” [9, 10]. In this context, it is very useful to distinguish between different notions 
of function. Philosophers have argued for decades about different concepts and meanings of the word 
‘function’ [11, 12]. The two biggest classes of alternative accounts originate back to Robert Cummins' 
“causal role” account [13] and Larry Wright’s “selected effects” notion of function [14]. Disputes 
between these camps continue to this day, but in the briefest way I can put it, the causal role account 
aims at explaining how something can do what it does, whereas the selected effects account strives to 
illuminate why an organism’s trait, capacity or feature can do what it does. I believe that these are two 
very different explanatory goals that justify having different notions of function. However, when they 
are confused for each other, they give rise to serious misunderstandings. A conceptual analysis with 
philosophical tools can be helpful for avoiding these misunderstandings. 
A very useful distinction of four different notions has been suggested by Arno G. Wouters [15]: On the 
one hand, we have function as biochemical activity (fctact), and on the other hand, we have the biological 
role (fctrole) as a functional contribution to a complex capacity at a higher level of organization. These 
cannot be linked to a single entity or activity, but rather to an entire mechanism network of entities and 
activities, which together give rise to the functional aspect of the biological role in question. In short, 
fctrole cannot be explained at the level of str3D and fctact; it can only be explained with reference to 
another kind of organizational network structure (strorg). In addition to these two causal role notions of 
function, there are two more evolutionary considerations of function (fctevol) to be distinguished: 
biological advantage and selected effect. Since we are not concerned with evolutionary considerations 
in this paper, I will refer to both of these aspects as “fctevol”. Especially when it comes to the relationships 
of structures and functions, evolutionary questions will be beyond the physiological aspects of the other 
notions of structure and function. Instead, they address why some of them show a different persistence 
by natural selection. On the physiological scale, however, higher levels of strorg can easily be imagined: 
from intra- and intercellular signaling networks and physiological mechanisms to social networks of 
populations, whose dynamics play a major role in the control of diseases in networks with community 
structure. 
Relationships between different notions of structure and function 
With this distinction of various notions of structure and function in mind, it is time to address their 
relationships. As briefly discussed earlier, the reductionist ideal of a linear chain of determination from 
sequence to structure to function does not work. Protein folding predictions have been quite successful 
due to the fact that the folding space appears to be quite modular with a number of repeated folding 
motifs [16]. Usually, a high degree of sequence similarity is a good indication of a similar str3D. The 
successful prediction of the biochemical activity of a protein usually depends on knowledge of the 
activity of a protein with a very similar str3D. Even though not a perfect proxy, it is a usually a good 
indicator for a conserved protein domain with similar biochemical properties and thus activities in a 
different protein. Its biological role, however, cannot be predicted solely by its str3D and comparison to 
similar str3D. Think, for example, of all the hundreds of different kinases. While they all share the same 
basic biochemical activity, i.e., catalyzing phosphorylation, their biological roles can be completely 
different [17], depending on the interaction network strorg they are part of – and their dynamics. 
A similar distinction can be made between antigenicity and immunogenicity, the confusion of which 
contributes to the conceptual problems of developing a structure-based HIV-1 vaccine [4, 18]. Attempts 
to develop vaccines, or to understand and intervene in biological systems in general, based solely on 
predictions from str3D is inherently limited. Once the different structure-function relationships have been 
spelled out in detail, many problems and misunderstandings can be clarified. The hope to predict a 
molecule’s ability to trigger an immune response and provide long-term immunity solely based on its 
str3D and binding capacities (fctact) is in vain – although it is a central assumption in structure-based 
reverse vaccinology attempts. 
Table 1 provides an overview of the different notions and their relations. All of them are exception-
ridden and face some non-trivial problems, defying the simple reductionist ideal of being determined 
from the “lower-level” notions. Pitting these levels or notions against each other as more fundamental 
would be a fruitless enterprise. In the same way, all of the different aspects and notions of structure and 
function are important for explaining different phenomena; it is important to have a molecular and 
systems perspective [19]. This is a general lesson for biology, and it is particularly important for 
interventions aiming at eliciting appropriate immune responses and long-term immunity in individuals 
and populations. 
Table 1 Different notions of structure and function, between which a meaningful relationship can be 
established. ‘Δstr/fct’ refers to evolutionary changes in structure or function. 
Notion of structure or function Relates to Kind of relation 
strseq str3D Genetic code, protein folding 
str3D fctact Correlation, modular build of 
protein domains 
strorg fctrole Network dynamics, systems 
biology 
Δstr/fct fctevol Natural selection, fitness 
advantage 
 
Antigenicity ≠ immunogenicity ≠ immunity 
Why do the intricate details of these structure-function relationships matter for vaccination design? One 
major obstacle in the attempts to develop such a “bottom-up”, reductionist, structure-based vaccine [20, 
21] rests on the simplistic, unwarranted assumption that str3D can be linked straightforwardly to fctact 
and fctrole. Failing to acknowledge the difference between the biochemical activity (fctact) and the 
biological role (fctrole), such as epitope binding and immunogenicity, results in misunderstandings and 
neglect of immunological theory [22]. As Marc H. V. Van Regenmortel put it: 
    The reductionist mindset made immunologists accept that the biological activities of Abs 
[antibodies] could be explained by their 3D structures and that the immunogenic potential of a 
viral epitope could be deduced from its antigenic properties. Biological immunogenicity was 
thereby reduced to chemical antigenicity, which is a variation of the claim that biology can be 
reduced to chemistry [...]. Such a claim fails to recognize that the protection achieved by 
vaccination is a biological phenomenon that has meaning only in the context of an entire 
organism since organs, tissues, or molecules cannot be vaccinated. Protection always results 
from a complex network of dynamic interactions between pathogen, host, and immune system 
and it cannot be satisfactorily understood when innumerable, individual molecular interactions 
are analyzed separately. [23] 
With the proposed distinction of different notions of structure, function, and their structure-function 
relationships, it is easy to see why the underlying fallacy is a confusion of different categories of 
functions. The same is true for the level of structures involved, as he also rightly points out that 
molecules cannot be vaccinated. The target of vaccination and the level at which immunogenicity can 
take place is not strseq or str3D, it is strorg [20, 24]. 
The problems may lie even deeper, with a focus on things rather than the underlying processes. Only 
the activities and functions result in antigenicity, immunogenicity, and protective immunity. These 
cannot be reduced to antigenicity, let alone be an intrinsic property of or be explained solely by any 
particular kind of structure. For that very reason, perhaps a process ontology perspective [25] is thus 
better suited for thinking about these issues in immunology. A similar case is being made to consider 
viruses as processes rather than things [26]. For the current question, however, we will stick with 
structure-function relationships and the general lesson that the functions (processes) of antigenicity, 
immunogenicity, and immunity we are interested in cannot be reduced to any structures. Structures 
should not be considered more fundamental than functions. Neither should these different functions be 
confused with each other. 
In addition, the notion of immunogenicity itself is something worth reconsidering conceptually [27]. 
Rather than basing immunological distinctions on notions of self and non-self, the spatio-temporal 
patterns of entities and their activities, a discontinuity of which would be the trigger for an immune 
response [28, 29], might be a better criterion for immunogenicity than the mere presence of a molecular 
str3D that we would classify as “foreign” or “dangerous”. And finally, immunogenicity, i.e., the 
successful induction of an immune response, is still not the same as the protective immunity that 
vaccines are ultimately aiming for. These issues need to be addressed in the complex context of both 
individual immune systems and populations – strorg at different levels of organization and their functions. 
With the distinction between fctact and fctroles, we can clearly see why str3D can be linked (imperfectly, 
with correlations) to fctact, such as antigenicity – even though there are also some non-trivial problems. 
However, a fctrole such as immunogenicity or protective immunity, which we are ultimately interested 
in when developing a vaccine, cannot be meaningfully linked to just fctact or str3D. If at all, strorg would 
need to be considered to understand the operations of immune systems at the level of their complex 
interaction networks. With systems immunology and systems vaccinology still in their infancy, we are 
far from such an extent of knowledge and understanding to venture with such an approach. It is doubtful 
whether the required completeness of knowledge about complex immune system interactions will ever 
be of an adequate quality to understand, let alone design, vaccines based on the strorg of these networks 
and their components and activities. 
Although it is a different kind of reductionism than basing everything solely on str3D, there is not much 
reason to be too optimistic about such attempts succeeding in the near future in developing HIV 
vaccines. It is not out of the question that major steps will be made in that direction, but it will be rather 
by “accident”, i.e., empirically by trial and error rather than based on knowing the primitive structural 
and functional components of these immune systems. Being aware of the distinctions and different 
relationships will be a helpful conceptual tool in avoiding such misconceptions and embarking on 
research paths that are most likely inherently doomed to fail. With this negative prospect of what has 
not worked in the past and the underlying conceptual problem of structure-function relationships, which 
alternatives might work? And how might a better understanding of structure-function relationships help 
in these endeavours? 
Can empirical approaches be more successful? 
Due to the evasive nature of HIV-1 structures and functions as a target for vaccination design, especially 
if designed rationally “bottom-up” with an emphasis on str3D, other alternatives might provide more 
expedient routes to developing a vaccine – or even ones with more promise of success: envisage 
treatment and cures. On the other hand, the most efficient way to stop the HIV/AIDS pandemic would 
still be a vaccine. While other approaches to preventing and treating HIV infection are showing 
fascinating and encouraging results, finding a vaccine remains a central challenge. In order to be 
successful, empirical approaches rather than “rational” design based on str3D might be more expedient. 
Reductionist, simplistic assumptions about structure-function relationships might be misleading and at 
the root of many failed approaches in the past [20, 30]. Despite the success of molecular, and especially 
structural, biology, there are a number of theoretical limits, which do not allow for the reductionist ideal 
to “explain all biology in terms of physics and chemistry” [31]. 
Returning to the “dirty little secret” of immunologists or vaccinologists, adjuvants such as aluminum 
hydroxide (or alum, for short) [32, 33] and their functions in addition to the str3D of antigens have to be 
taken into account – together with the strorg of complex interaction networks on different levels of 
organization. Once again, the processes of fctact and fctrole are responsible for the outcome, not just the 
structures that are involved. 
An interesting observation2 is the recent development of nanofiber vaccines that work without adjuvants 
[34]. While the underlying mechanisms are not yet completely understood, it is suspected that the mode 
of antigen delivery plays a crucial role in inducing immunity. The same is probably true for other 
adjuvant-free vaccines, such as some seasonal flu vaccines. Once again, this can be interpreted in a 
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conceptual framework where functions, not just structures, are an important factor for being recognized 
by the immune system and triggering an immune response [35]. 
With a better understanding of the working mechanisms of vaccine adjuvants [36, 37] – what they are, 
or are not, needed for – and of structure-function relationships, vaccination design could be able to 
combine empirical and rational approaches. In addition to adjuvants, there may be a number of other 
(unknown) factors that are also important for immunogenicity. Once we acknowledge the fctact and fctrole 
of adjuvants, they are “no longer a dirty little secret, but essential key players in vaccines of the future” 
[38]. Instead of neglecting immunological theories [22] and using outdated concepts of antibody 
specificity [23], future vaccination attempts should focus on notions of structure and function other than 
just str3D. Systems biology approaches to vaccination are a promising first step in this direction 
[39,40,41]. 
Taken together, the story of adjuvants and the mechanisms by which they function underscores that, for 
the immune system, “what is going on” might be more important than “who is there”, i.e., the functions 
rather than the structures could be the relevant difference makers for whether or not an immune response 
is triggered and whether or not a vaccine is successful in establishing immunity. In other words: 
processes instead of things [25]. For all of these alternative approaches and for keeping the relevant 
processes apart, an improved understanding of structure-function relationships should be helpful – at 
the very least, to avoid falling for certain conceptual misunderstandings that take a simplistic, 
reductionist view on structure and function. 
Conclusion and outlook 
Binding specificity, a central topic long neglected by philosophers of science, is now finally receiving 
more attention [42], especially with respect to drug design and HIV treatment [43]. In the past, 
immunology and vaccination design have put too much emphasis on str3D and steric complementarity, 
together with the concepts of causal specificity. Structure-based vaccination design faces some 
fundamental conceptual limits, neglecting the complexity [44] and importance of structure-function 
relationships. When approaching these and other central challenges in contemporary life sciences, it is 
useful to remember Orgel’s second rule: “evolution is cleverer than you are”. Instead of only trying to 
rationally design and reverse-engineer vaccines, taking advantage of nature’s complex structures and 
functions to study the relationships between them and their modes of operation must not be neglected. 
Thus, a better understanding of structure-function relationships might advance rational HIV vaccine 
design, open up other pathways of prevention and therapy, and help avoiding theoretical misconceptions 
that have posed a barrier in other areas of biology and medicine. Providing the required conceptual 
analysis is a way in which philosophy can contribute to such scientific problems [45] – in particular, 
when there are calls for a change of “paradigm” [46, 47]. While many “secrets” remain to be uncovered 
in vaccinology – and immunology in general – addressing them conceptually allows us to tackle them 
with novel experiments and empirical approaches; this way, they can inspire new lines of research rather 
than remaining “dirty little secrets”. 
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